“…Overall, these studies demonstrated that financial costs play a key role in countries without public funding for ART treatments, and could be offset through different mechanisms including increasing the availability of public funding for IVF, insurance coverage and clinic-sponsored incentives (e.g. free cryopreservation services and free transfer of cryopreserved embryos), and thereby change patient preferences (Coetzee et al, 2007, Griffin et al, 2012, Marek et al, 2005). The effects of financial incentives may be weaker in countries that provide free publicly funded IVF cycles and have higher uptake of SET, such as Denmark, Sweden and the Netherlands, compared with countries with no universal public funding for IVF (Blennborn et al, 2005, Højgaard et al, 2007, Kreuwel et al, 2013).…”